Delivery Order SPE2DB20D3103-SPE2DB23FM5Y8

Award Date 2/27/23
Potential Completion Date 2/28/23
Potential Value $2.9K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,128.44, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a medical product, with a performance period ending on May 21, 2025. This delivery order contract is a firm fixed-price type and is not set aside for any specific business category. Amerisourcebergen Drug Corp holds a...
This is a federal contract award issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $83,424.00, is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a pharmaceutical product, and has an ultimate completion date of January 21, 2022. The contract is a Delivery Order with a Firm Fixed Price pricing type, and there is no set-aside designation. Amerisourcebergen Drug Corp is a major...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,118.34 firm fixed-price delivery order is for the pharmaceutical product Visipaque 320 mg/ml, a bottle of 100 ml. The award has an ultimate completion date of January 31, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
This federal contract award, valued at $1,099.37, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order for the medical product Visipaque 320 mg/ml infusion bottles, 150 ml. This award is not associated with a set-aside program and falls under the company's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
This federal contract award, valued at $1,650.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order contract for the supply of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a medical product. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 30, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,265.73, is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a pharmaceutical product. The award is a Delivery Order under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,929.53, is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a medical product. The contract is a Firm Fixed Price Delivery Order with a performance period ending on March 31, 2025. This contract award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen...
This federal contract award was granted to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is a firm fixed price delivery order for the supply of VISIPAQUE 320 MG/ML, a pharmaceutical product, with a ceiling value of $2,795.85 and a performance period through March 15, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through...
This federal contract award is for the delivery of VISIPAQUE 320 MG/ML BOTTLE 100ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $2,943.00 fixed-price delivery order was awarded to the prime contractor, AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 3, 2022 and is not designated with a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a pharmaceutical product, with a ceiling value of $1,650.56. It is a firm fixed price delivery order contract, with a period of performance ending on June 18, 2025. The contract is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant Indefinite...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB23FM5Y8
    Delivery Order

This federal contract award, valued at $2,869.70, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a pharmaceutical product, to support federal government healthcare programs.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which runs through December 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract award reviewed is a delivery order issued under this IDC. There was no set-aside designation for this contract.

Generated 2/27/25, 10:07 AM